Get the app
US › Healthcare

Barinthus Biotherapeutics plc (BRNS)

US · Healthcare · Biotechnology

$0.740.00%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue
$0
Net profit
$-10.6M
EPS
$-0.26
EPS estimate
$-0.28

EPS came in at -0.26 against a street estimate of -0.28 — a beat of 7.1%.

Key statistics

Market cap
$30.2M
Forward P/E
0.0
P/B
0.53
Book value
$1.40
EPS (TTM)
$-1.02
52-week high
$1.83
52-week low
$0.51
50-day MA
$0.63
200-day MA
$0.66
Beta
-0.36

Analyst view

Analysts rate Barinthus Biotherapeutics plc a strong buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $6.00.

Shareholding

Insiders
19.81%
Institutions
44.07%

Largest institutional holders

FundStake
M&G PLC12.72%
HSG Holding Ltd3.48%
GLR Partners, LLC3.04%
DC Funds, LP1.57%
Renaissance Technologies Corp0.37%
The Johns Hopkins University0.30%
Baird Financial Group, Inc.0.26%
Citadel Advisors Llc0.19%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Barinthus Biotherapeutics plc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncMerck & Company IncUnitedHealth Group IncorporatedNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncNovo Nordisk A/SGilead Sciences IncAbbott Laboratories

Data updated 2026-09-18.